Stopped: Voluntarily terminated due to benefit/risk assessment
The main purpose of this study is to assess the efficacy and safety of daily and intermittent dosing of MK-1942 compared to placebo among participants with Treatment-Resistant Depression (TRD) on a stable course of antidepressant therapy. The dual primary hypotheses of the study are that the daily MK-1942 treatment or intermittent MK-1942 treatment are superior to placebo in reducing Montgomery-Asberg Depression Rating Scale (MADRS) score.
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Change From Baseline in Montgomery-Asberg Depression Rating Scale (MADRS) Total Score to Week 3
Timeframe: Baseline and Week 3
Change From Baseline in MADRS Total Score to Week 1
Timeframe: Baseline and Week 1
Number of Participants Who Experienced An Adverse Event (AE)
Timeframe: Up to approximately 6 Weeks
Number of Participants Who Discontinued Study Treatment Due to an AE
Timeframe: Up to approximately 4 Weeks